Eli Lilly and Company (LLY)
Surprise: Eli Lilly Is Racing Toward Yet Another Blockbuster
Eli Lilly's once-weekly insulin product just aced phase 3 studies. The company will battle its eternal rival, Novo Nordisk, in this market.
Lilly (LLY) Hits Record High on Crohn's Disease Study Data
Eli Lilly's (LLY) stock hits an all-time high after announcing detailed results from a late-stage study on mirikizumab in Crohn's disease.
Eli Lilly Rises As Study Shows Omvoh Successful in Treating Crohn's Disease
Shares of Eli Lilly (LLY) were on track to close at an all-time high Tuesday as a study showed the pharmaceutical giant's current drug for ulcerative colitis also was successful in treating Crohn's disease.
Healthy Returns: Eli Lilly, Novo Nordisk are competing to develop more convenient weekly insulins
The rivalry between Eli Lilly and Novo Nordisk extends beyond weight loss and diabetes drugs. Meanwhile, Uber has announced new features for caregivers.
Eli Lilly's stock on pace for record close as Crohn's disease trial hits the mark
Eli Lilly & Co. LLY shares were on pace for a record closing high Tuesday after the drugmaker released data from a late-stage Crohn's disease trial and struck a deal to develop new cancer-targeting medicines.
If You'd Invested $10,000 in Eli Lilly Stock 5 Years Ago, Here's How Much You'd Have Today
Eli Lilly's weight loss drugs are driving growth at the pharma company, generating billions of dollars in revenue. This could continue, considering the strong demand for the products.
Aktis to collaborate with Eli Lilly on cancer therapies
Aktis Oncology said on Tuesday it will collaborate with Eli Lilly to develop cancer therapies, making it eligible for milestone payments of up to $1.1 billion and royalties on sales.
Eli Lilly's (LLY) diabetes injection Mufenda gets approval in China
Eli Lilly and Company announced on Tuesday that the National Medical Products Administration (NMPA) in China has approved the distribution of its injection Mufenda. This injection is designed to treat diabetes, improve blood sugar control, and aid in weight loss for adults with type 2 diabetes.
Eli Lilly's (LLY) diabetes injection Mufenda gets approval in China
Eli Lilly and Company announced on Tuesday that the National Medical Products Administration (NMPA) in China has approved the distribution of its injection Mufenda. This injection is designed to treat diabetes, improve blood sugar control, and aid in weight loss for adults with type 2 diabetes.
Eli Lilly's diabetes drug tirzepatide gets approval in China
Eli Lilly said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting up intensifying competition with its Danish rival Novo Nordisk in the key Asian market.
Here's How Much $100 Invested In Eli Lilly and Co 5 Years Ago Would Be Worth Today
Eli Lilly and Co LLY has outperformed the market over the past 5 years by 32.88% on an annualized basis producing an average annual return of 46.32%. Currently, Eli Lilly and Co has a market capitalization of $744.41 billion. Buying $100 In LLY: If an investor had bought $100 of LLY stock 5 years ago, it would be worth $670.53 today based on a price of $783.25 for LLY at the time of writing. Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by an editor. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Pharma Stocks Outlook: Where Are 2024's Top Performers Headed Next?
The three top performing stocks discussed below have appreciated in value by an average of 129.7% in 2024. Such torrid growth logically raises the question of what is possible moving forward.
